RecruitingRecruiting
A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder
NCT07767903 · Otsuka Pharmaceutical Development & Commercialization, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial to Compare the Efficacy and Safety of a Fixed Dose of SEP-363856 to Placebo in the Treatment of Adults With Generalized Anxiety Disorder
About this study
This is a global, phase 3, randomized, double-blind, parallel-group, 2-arm, placebo controlled, multicenter trial designed to compare the efficacy, safety and tolerability of a fixed dose of SEP-363856 (75 millligrams per day \[mg/day\]) to placebo over an 8-week double-blind treatment period in adults with generalized anxiety disorder (GAD).
Eligibility criteria
Key Inclusion Criteria
1. Male or female participants at least 18 years of age at the time of informed consent
2. Primary diagnosis of GAD per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by Mini-International Neuropsychiatric Interview (MINI) and clinical psychiatric evaluation
3. Body Mass Index (BMI) 18-40 kilograms per square meter (kg/m\^2)
4. Participant is willing and able to comply with study procedures and visit schedule
5. Medically stable as determined by medical history, physical exam, vital signs, and laboratory tests and able to comply with study procedures
6. Willing and able to discontinue prohibited medications/therapies per protocol
7. (i ) Females of childbearing potential: negative pregnancy test and agreement to use acceptable contraception (ii) Males: agreement to follow protocol-defined contraception and reproductive restrictions
8. Willing and able to discontinue prohibited medications/therapies per protocol
Key Exclusion Criteria
1. Current DSM-5 diagnosis of major depressive episode, post traumatic stress disorder (PTSD), or any psychiatric disorder other than GAD that was the primary focus of treatment within 12 months prior to screening
2. Substance use disorder (excluding nicotine/caffeine) within 12 months prior to screening
3. Lifetime history of certain psychiatric disorders (e.g., schizophrenia spectrum disorders, bipolar disorder, obsessive-compulsive disorder, borderline or antisocial personality disorder)
4. Significant suicide risk e.g., recent suicidal behavior/ideation per Columbia-Suicide Severity Rating Scale \[C-SSRS\] or MADRS)
5. Use of prohibited medications/therapies within protocol-defined timeframes (e.g., certain antipsychotics, mood stabilizers, benzodiazepines, investigational treatments)
6. Prior exposure to restricted treatments
7. Pregnant or breastfeeding females
8. Participation in another investigational study within 180 days (or more than \[\>\] 1 trial in last year)
9. Known history of human immunodeficiency virus seropositivity, hepatitis B or C
Study design
Enrollment target: 384 participants
Allocation: randomized
Masking: triple
Age groups: adult, older_adult
Timeline
Starts: 2026-08-06
Estimated completion: 2028-11-01
Last updated: 2026-11-12
Interventions
Drug: SEP-363856Drug: Placebo
Primary outcomes
- • Change From Baseline at Week 8 in Hamilton Anxiety Rating Scale (HAM-A) Total Score (Baseline, Week 8)
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. · industry
Contacts & investigators
ContactOtsuka Call Center · contact · ProfessionalServices@otsuka-us.com · 844-687-8522
All locations (21)
IMA Clinical Research - PhoenixRecruiting
Phoenix, Arizona, United States
Calneuro Research GroupRecruiting
Los Angeles, California, United States
Anderson Clinical ResearchRecruiting
Redlands, California, United States
Schuster Medical Research Institute SMRIRecruiting
Sherman Oaks, California, United States
Concierge Clinical TrialsRecruiting
Valley Village, California, United States
Velocity Clinical Research - Hallandale BeachRecruiting
Hallandale, Florida, United States
Clinical Neuroscience Solutions Inc. (CNS) - OrlandoRecruiting
Orlando, Florida, United States
ActivMed Practices & Research, LLCRecruiting
Methuen, Massachusetts, United States
Adams Clinical - WatertownRecruiting
Watertown, Massachusetts, United States
Lumina Clinical Research CenterRecruiting
Cherry Hill, New Jersey, United States
Basil ClinicalRecruiting
Jamaica, New York, United States
IMA Clinical Research NYC UptownRecruiting
New York, New York, United States
Adams Clinical - BronxRecruiting
The Bronx, New York, United States
Paradigm Research Professionals LLCRecruiting
Oklahoma City, Oklahoma, United States
Summit Research NetworkRecruiting
Portland, Oregon, United States
Adams Clinical PhiladelphiaRecruiting
Philadelphia, Pennsylvania, United States
CNS Healthcare - MemphisRecruiting
Memphis, Tennessee, United States
Donald J. Garcia, Jr, MD, PARecruiting
Austin, Texas, United States
DM Clinical Research - BellaireRecruiting
Houston, Texas, United States
Vitra Behavioral and Metabolic Research CenterRecruiting
Fairfax, Virginia, United States
Core Clinical ResearchRecruiting
Everett, Washington, United States